Pharmaceutical Executive, Oct 1, 2008 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Oct 1, 2008
Features
Stop the Bleeding
Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage.
Global Warming
By Walter Armstrong
Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?
Evolving Clinical Trials
Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in effciency.
Getting Personal(ized)
Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.
The D-Mab Men
By Joanna Breitstein
Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug.
Columns
Seasoned Leaders
By Jim Zuffoletti
Enter the Maturity Matrix: the future of KOL management organization.
Remodeling Your Sales Force
It's management makeover time—and micromanaging is so last year.
What's The Buzz
What's the buzz all about? Word of mouth is more effective than we think.
Getting "Engaged"
Web analystics is helping a new generation of pharma web sites get engaged.
Washington Report
Part D Under Attack
By Jill Wechsler
Congressional leaders ready campaign to curb Medicare drug plans.
Back Page
The Drug Vote '08
By Walter Armstrong
A head-to-head comparison of the Drug Vote '08
Global Report
Open For Debate
By Sarah Houlton
Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems
Thought Leader
Specialty Sales Gets No Resistance
Cubist Pharmaceuticals CEO Michael Bonney has given the company a successful start—and is now predicting the future of drug resistance.
Leadership
Going for Gold
By Sander Flaum
Try this one on for size: Multi-tasking isn't the path to greatness
From the Editor
Future Shock
By Patrick Clinton
A vision of pharma's next business model is starting to emerge. But how do we get from here to there?

ADVERTISEMENT

Click here